Literature DB >> 19945761

Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.

Jiang-Yi Yu1, Xiao-Fei An, Jing-Shun Liu, Shi-Chao Ten, Xin Wang, Yue Zhao, Sha Huang, Wan-Jian Gu, Feng Gao.   

Abstract

AIMS: The interaction of advanced glycation end products (AGEs) and the receptor for advanced glycation end products (RAGE) has played an important role in the pathogenesis of diabetic nephropathy. In the present study, we measured the relationship of plasma soluble isoform of RAGE (sRAGE) and urinary microalbumin excretion in the early stage of type 2 diabetic nephropathy.
METHODS: 180 patients with early stage of type 2 diabetic nephropathy were recruited into the study. Plasma sRAGE and the characterized AGE carboxymethyllysine (CML) were measured by enzyme-linked immunosorbent assay.
RESULTS: Plasma sRAGE positively correlated with the level of CML (R=0.22, P=0.03) while sRAGE was not significantly correlated with the urinary mAlb/Cr (R=0.15, P=NS). On stepwise linear regression analysis, AGE and GFR were the main independent determinants of plasma sRAGE concentration.
CONCLUSION: Plasma sRAGE is not significantly associated with urinary microalbumin excretion in the early stage of diabetic nephropathy while it is correlated positively with circulating AGE and negatively with glomerular filtration rate (GFR). 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945761     DOI: 10.1016/j.diabres.2009.11.002

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

1.  Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.

Authors:  Tina E Brinkley; Xiaoyan Leng; Barbara J Nicklas; Stephen B Kritchevsky; Jingzhong Ding; Dalane W Kitzman; W Gregory Hundley
Journal:  Metabolism       Date:  2017-02-10       Impact factor: 8.694

2.  Analysis of advanced glycation end products in the DHS Mind Study.

Authors:  Jeremy N Adams; Susan E Martelle; Laura M Raffield; Barry I Freedman; Carl D Langefeld; Fang-Chi Hsu; Joseph A Maldjian; Jeff D Williamson; Christina E Hugenschmidt; J Jeffery Carr; Amanda J Cox; Donald W Bowden
Journal:  J Diabetes Complications       Date:  2015-11-30       Impact factor: 2.852

3.  Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.

Authors:  Colomba Falcone; Maria Paola Buzzi; Sara Bozzini; Chiara Boiocchi; Angela D'Angelo; Sandra Schirinzi; Ciro Esposito; Massimo Torreggiani; Jasmine Choi; Michael Ochan Kilama; Giuseppe Mancia
Journal:  Mediators Inflamm       Date:  2012-02-13       Impact factor: 4.711

4.  Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.

Authors:  Jenny M Wadén; Emma H Dahlström; Nina Elonen; Lena M Thorn; Johan Wadén; Niina Sandholm; Carol Forsblom; Per-Henrik Groop
Journal:  Diabetologia       Date:  2019-05-24       Impact factor: 10.122

5.  Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes.

Authors:  Elaine Hui; Chun-Yip Yeung; Paul C H Lee; Yu-Cho Woo; Carol H Y Fong; Wing-Sun Chow; Aimin Xu; Karen S L Lam
Journal:  J Clin Endocrinol Metab       Date:  2014-08-28       Impact factor: 5.958

6.  Plasma heparanase is associated with blood glucose levels but not urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.

Authors:  Yue Zhao; Jingshun Liu; Shichao Ten; Jisheng Zhang; Yanggang Yuan; Jiangyi Yu; Xiaofei An
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.